In fiscal year 2025, Xcell Therapeutics (373110) reported revenue of 1.9 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 1.9 billion KRW | -10.9 billion KRW | -10.9 billion KRW | [source] |
| 2024 | 1.9 billion KRW | -9.3 billion KRW | -9.5 billion KRW | [source] |
| 2023 | 1.1 billion KRW | -8.7 billion KRW | -9.3 billion KRW | [source] |
| 2022 | 1.0 billion KRW | -8.3 billion KRW | -8.3 billion KRW | — |
| 2021 | 2.0 billion KRW | -5.7 billion KRW | -9.0 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 15.9 billion KRW | 8.6 billion KRW | 7.3 billion KRW | [source] |
| 2024 | 17.0 billion KRW | 7.8 billion KRW | 9.3 billion KRW | [source] |
| 2023 | 10.6 billion KRW | 8.1 billion KRW | 2.5 billion KRW | [source] |
| 2022 | — | — | — | — |
| 2021 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.